Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily Biotech Top 5 Bull 2X ETF

43.55
-0.8661-1.95%
Volume:5K
Turnover:221.49K
Market Cap:5.44M
PE:- -
High:43.80
Open:43.80
Low:43.46
Close:44.42
52wk High:45.10
52wk Low:25.71
Shares:125.00K
Float Shares:125.00K
Volume Ratio:1.22
T/O Rate:4.06%
Dividend:0.62
Dividend Rate:1.43%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong

Dow Jones
·
Aug 05

Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting

Reuters
·
Aug 05

Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333

THOMSON REUTERS
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Amgen Inc : Oppenheimer Raises Target Price to $450 from $400

THOMSON REUTERS
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Amgen Announces Availability of Q2 2026 Earnings Report Release

Reuters
·
Aug 05

Amgen's Strong Second Quarter Drug Sales Drive Upward Forecast Revision and Early-Stage Weight Loss Drug Termination

Deep News
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05

Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Amgen Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Amgen Exec Says Continues to Expect Capital Expenditures of About $2.6 Billion in 2026 to Scale Manufacturing Capacity, Including for Maritide's Launch

THOMSON REUTERS
·
Aug 05

Amgen Exec Says Expect a Meaningful Sequential Increase in Operating Expenses in the Third Quarter

THOMSON REUTERS
·
Aug 05